Seroba Life Sciences
Seroba Life Sciences is a venture capital firm based in Dublin, Ireland, with an additional office in London, United Kingdom. Established in 2002, the firm specializes in investments in the life sciences sector, targeting therapeutics, healthcare technologies, medical devices, and diagnostics. Seroba primarily invests in Series A and B stage companies, often at early clinical or preclinical development stages, with a typical investment range of €3 million to €10 million per company. The firm aims to support innovative healthcare opportunities, partnering with entrepreneurs to navigate the complexities of development, regulatory approval, and market launch. Seroba focuses its investments mainly in Western Europe and North America, leveraging its team's scientific, medical, regulatory, and commercial expertise to enhance the potential of its portfolio companies and improve patient outcomes.
Perfuze develops technology to treat acute ischemic stroke. The company was founded in 2018 and is based in Galway, Ireland.
Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products.
The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials.
It was established in Galway, Galway in 2013.
Shorla Pharma Limited is an Irish specialty pharmaceutical company that focuses on developing and manufacturing oncology drugs specifically targeting orphan and pediatric cancers. Established in 2017 and headquartered in Clonmel, Ireland, with an additional office in New York, the company offers products such as SH-111, a sterile injectable solution for treating T-cell leukemia in both pediatric and adult patients, and SH-105, another oncology drug. Shorla Pharma is committed to providing accessible and affordable life-saving treatments, contributing significantly to patient care and making a meaningful clinical impact in the field of oncology.
Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products.
The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials.
It was established in Galway, Galway in 2013.
Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products.
The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials.
It was established in Galway, Galway in 2013.
Apica Cardiovascular is a pre revenue medical device company commercializing a technology for access and closure of the heart’s apex and the peripheral vascular system. The underlying technology has applications in a number of medical procedures such as Transcatheter Heart Valves (TAVI), AAA, and LVAD implantation. The technology standardizes access and closure for large bore therapeutic devices without loss of blood via minimally invasive surgical or percutaneous access on the beating heart. The technology has progressed to the point where it has proven the initial concept in animal and cadaver models and is now moving toward initial clinical trials.
Biosensia is a Point-of-Care in-vitro diagnostics company that has a novel point-of-care platform, RapiPlex, available for licensing.
RapiPlex combines highly innovative technologies to produce a practical, rapid, multiplexing POC in-vitro diagnostics (IVD) platform, enabling access to a broad range of diagnostic applications.
Its component chip and cartridge system are compatible with a variety of common biological sample types, including whole blood, serum, saliva, urine and nasal/genital swabs.
NOvate Medical Technologies is a New Orleans-based medical device development company, focused on commercializing high-quality, low-cost, and sustainable medical products while addressing critical global health needs. NOvate’s first product offering, InfaClip, previously known as SafeSnip, is a patented disposable plastic obstetric device that simultaneously cuts, clamps, and shields the infant, mother, and birthing attendant from infection, aimed at reducing maternal and neonatal mortality in developing countries.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Biosensia is a Point-of-Care in-vitro diagnostics company that has a novel point-of-care platform, RapiPlex, available for licensing.
RapiPlex combines highly innovative technologies to produce a practical, rapid, multiplexing POC in-vitro diagnostics (IVD) platform, enabling access to a broad range of diagnostic applications.
Its component chip and cartridge system are compatible with a variety of common biological sample types, including whole blood, serum, saliva, urine and nasal/genital swabs.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.